The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

The “AMR Conference” was started in 2017 as part of the annual “Berlin Conference on Life Sciences” series which was established by BIOCOM AG twelve years ago as an event format to discuss the challenges of SME-driven innovation for the health market and to offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs and intellectual property.

Each day will offer an AMR briefing session in the afternoon (starting at 2pm CET) on a dedicated topic, including live speakers, high-level panel discussions, and interactive exchange with the audience:

• Day 1 – Status quo & COVID-19 Impact: What has changed after one year of COVID?
• Day 2 – Financing & Investing: What’s new with funds, incubators and accelerators?
• Day 3 – Policy & Incentives: What can we learn from best practices to go ahead?

CARB-X participants include Erin Duffy, Chief of R&D, who is a speaker on the session “Focus on incubators and public-private accelerators in US and Europe – How they drive the AMR innovation pipeline” on Wednesday, August 25th at 3:00 p.m. – 4:15 p.m. CEST, and Kevin Outterson, Executive Director, who is a speaker on the session “What can we expect and learn from the US and UK pull incentive initiatives?” on Thursday, August 26th at 02:00 p.m. – 03:15 p.m. CEST

Click here to learn more.
Click here to view the agenda.
Click here to register.